---
title: CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells
date: '2024-03-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38437507/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240305170531&v=2.18.0.post9+e462414
source: Blood
description: Relapsed or refractory Acute Myeloid Leukemia (AML) remains a major therapeutic
  challenge. We have recently developed a V1+  T-cell-based product for adoptive
  immunotherapy, named Delta One T (DOT) cells, and demonstrated their cytolytic capacity
  to eliminate AML cell lines and primary blasts in vitro and in vivo. However, the
  molecular mechanisms responsible for the broad DOT-cell recognition of AML cells
  remain poorly understood. Here we dissected the role of NK-cell receptor ligands
  in ...
disable_comments: true
---
Relapsed or refractory Acute Myeloid Leukemia (AML) remains a major therapeutic challenge. We have recently developed a V1+  T-cell-based product for adoptive immunotherapy, named Delta One T (DOT) cells, and demonstrated their cytolytic capacity to eliminate AML cell lines and primary blasts in vitro and in vivo. However, the molecular mechanisms responsible for the broad DOT-cell recognition of AML cells remain poorly understood. Here we dissected the role of NK-cell receptor ligands in ...